Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 7/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | PDE5A | O76074 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SCD | O00767 | 8/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4865974 | 0.89 | AOC3 (0.58) | AOC3NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5549591 | 0.83 | AOC3 (0.55) | AOC3NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4874675 | 0.81 | AOC3 (0.63) | AOC3KDM4EPDE5ANPC1RAB9A | |
| SCHEMBL27782868 | 0.79 | AOC3 (0.74) | AOC3KDM4EPDE5ANPC1RAB9A | |
| SCHEMBL4990295 | 0.79 | AOC3 (0.53) | AOC3KDM4EPDE5ANPC1RAB9A | |
| SCHEMBL5545486 | 0.77 | AOC3 (0.53) | AOC3NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4867212 | 0.77 | AOC3 (0.58) | AOC3NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4870584 | 0.77 | AOC3 (0.58) | AOC3NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4874993 | 0.77 | AOC3 (0.74) | AOC3KDM4EPDE5ANPC1RAB9A | |
| SCHEMBL13679462 | 0.76 | AOC3 (0.70) | AOC3KDM4EPDE5ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080119462-A1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | SUCAMPO AG (CH) | 2008-05-22 | — | — | US | disclosed |
| EP-1608365-A1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | Sucampo AG (CH) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004087138-A1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | SUCAMPO AG (CH) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119462-A1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | VCAM1, ICAM1, VAPB | AOC3 202/4885KDM4E 3439/4885PDE5A 1085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.